Ignite Creation Date:
2024-10-26 @ 3:38 PM
Last Modification Date:
2024-10-26 @ 3:38 PM
Study NCT ID:
NCT06559072
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-08-14
Brief Title:
Ultra-early STatin in Patients With Aneurysmal subaRachnoid Hemorrhage Ue-STAR
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Ultra-early STatin in Patients With Aneurysmal subaRachnoid Hemorrhage Ue-STAR a Randomized Controlled Trial
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
Ue-STAR
Brief Summary:
A researcher-initiated and conducted multicenter randomized controlled trial aimed at evaluating the efficacy and safety of ultra-early statin therapy in the treatment of acute aneurysmal subarachnoid hemorrhage aSAH
Detailed Description:
To further explore the efficacy and safety of ultra-early statin administration in aSAH the investigators propose a Phase III randomized controlled trial-The Ultra-early Statin in patients with Aneurysmal subArachnoid hemorrhage Ue-STAR trial This study aims to determine whether ultra-early within 6 hours short-term treatment 2 weeks with a high intensive long-acting statin atorvastatin 40 mgday improves clinical outcomes at 6 months in aSAH patients Through this research the investigators hope to provide more robust evidence for the clinical management of aSAH ultimately improving treatment outcomes for patients
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None